article · Frontiers in Pharmacology
cohort. The authors call for the development of predictive biomarkers and novel drug combinations to further enhance outcomes.In conclusion, the contributions to this Special Topic section underscore the dynamic and multifaceted nature of resistance to tumour angiogenesis therapies. By identifying new molecular targets, validating innovative combination therapies, and emphasising the significance of patient stratification, these studies provide guidance for developing more effective and sustainable antiangiogenic strategies. Overcoming resistance will require continued collaboration across disciplines, integration of emerging scientific insights, and a steadfast commitment to patient-centred care.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3389/fphar.2026.1801844
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
